- Details
- Robotic Surgeon Ketan Badani, MD, joins Jaime Landman, MD, and Monty Pal, MD, to discuss the paper, “The Effect of 3-Dimensional Virtual Reality Models for Surgical Planning of Robotic-Assisted Partial Nephrectomy on Surgical Outcomes” for Kidney Cancer today. Dr. Badani describes the outcomes of this clinical trial, which randomized patients receiving partial nephrectomy to the usual preoperative...
|
- Details
- PDIGREE is a novel adaptive frontline immunotherapy study which upon completion will help answer many important questions regarding treatment duration, when to combine VEGF therapy with IO therapy, and which patients benefit most from IO-VEGF combination upfront vs. sequential therapy. This trial is actively enrolling patients at all National Clinical Trials Network (NCTN) study sites. The primary...
|
- Details
- Recorded Date: March 27, 2020 Jaime Landman and Monty Pal moderate this discussion featuring Dena Battle and Michael Staehler. "In the wake of the COVID-19 outbreak, governments and hospital systems are struggling to determine how to continue to provide care when resources are seriously compromised. Dena Battle, president of KCCure ran a patient survey from March 22 to March 25, asking patients to...
|
- Details
- In this episode of Kidney Cancer Today, Monty Pal and Jamie Landman team up with Laura Bukavina and Lee Ponsky to discuss consults for benign renal cysts undergoing unnecessary active surveillance. Among other topics, their conversation especially touches on present flaws in the healthcare system, including the appropriate evaluation of renal cysts and healthcare disparities in accessibility to ac...
|
- Details
- In this episode of Kidney Cancer Today, Jaime Landman helps Monty Pal dissect some of the biggest issues on active surveillance for renal cell carcinoma. The following questions were discussed. Who is the right patient for active surveillance? Can a T1b patient be a candidate for active surveillance? What are the best clinical practices post five years after resection in the surveillance setting?...
|
- Details
- Shaan Dudani joins Monty Pal and Jaime Landman, sharing an overview of the First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium which was published this past August in European urology. Using the International Metastatic Renal-cell Carcinoma Database Consortium (IMDC) dataset, patient...
|
- Details
- Trinity Bivalacqua speaks about the principles of tissue engineering and how this relates to the production of a new urinary like tissue. Biographies: Trinity Bivalacqua, MD, Ph.D., Director of Urologic Oncology, Associate Professor of Urology, Johns Hopkins Medicine, Baltimore, Maryland, United States Related Content: Engineering & Urology Society: "Found in Translation"- Kurt Azarbarzin Read the...
|
- Details
- Tian Zhang, MD and Monty Pal, MD review first-line therapy options for metastatic renal cell carcinoma (mRCC), including immunotherapy- based ipilimumab, nivolumab, pembrolizumab, axitinib, as well as avelumab/axitinib combinations and cabozantinib monotherapy. Tian continues focusing on achieving a complete response rate, and treating intermediate, poor-risk disease where she describes an excitin...
|
- Details
- Neeraj Agarwal, MD discusses the recent update to the CARMENA trial which was presented at ASCO 2019. The Phase 3 non-inferiority CARMENA trial comparing sunitinib versus nephrectomy followed by sunitinib established that patients could avoid nephrectomy without compromising survival. This benefit was seen in both the intermediate and poor risk subgroups. In the updated data presented at ASCO 2019...
|
- Details
- Tian Zhang and Alicia Morgans discuss the three new approvals for the first line treatment of metastatic renal cell carcinoma, including cabozantinib with targeted agents, IO combinations with ipilimumab and nivolumab and now the recent approval of pembrolizumab plus axitinib. Dr. Zhang reviews the long-term follow-up from the CHECKMATE-214 study along with the CABOSUN data. The discussion conclud...
|
